Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy

Cancer

Volumn 117, Issue 22, 2011, Pages 5029-5038

  Salonia, Andrea ^a   Gallina, Andrea ^a   Briganti, Alberto ^a   Suardi, Nazareno ^a   Capitanio, Umberto ^a   Abdollah, Firas ^a   Bertini, Roberto ^a   Freschi, Massimo ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

17 ; estradiol; high grade prostate cancer; prostate cancer; radical prostatectomy; testosterone

Indexed keywords

ESTRADIOL; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CANCER PATIENT; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TUMOR CLASSIFICATION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 80054756183     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26136     Document Type: Article

References (49)

1. Van Poppel H, Joniau S,. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008; 53: 253-259. (Pubitemid 350296585)
2. Rodriguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L,. The outcome of patients with pathological Gleason score âyen;8 prostate cancer after radical prostatectomy. BJU Int. 2008; 101: 305-307.
3. Alkhateeb S, Alibhai S, Fleshner N, et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol. 2010; 183: 145-150.
4. Moreira DM, Presti JC Jr, Aronson WJ, et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010; 105: 1541-1547.
5. Teeter AE, Banez LL, Presti JC Jr, et al. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH Database Group. J Urol. 2008; 180: 1980-1984.
6. Cheng L, Davidson DD, Lin H, Koch MO,. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer. 2007; 110: 1967-1972. (Pubitemid 350036855)
7. Isbarn H, Pinthus JH, Marks LS, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009; 56: 48-56.
8. Imamoto T, Suzuki H, Fukasawa S, et al. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy. Eur Urol. 2005; 47: 308-312. (Pubitemid 40248848)
9. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA,. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol. 2005; 173: 1935-1937. (Pubitemid 40675215)
10. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001; 47: 52-58. (Pubitemid 32246752)
11. Ho CK, Nanda J, Chapman KE, Habib FK,. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. J Endocrinol. 2008; 197: 483-491. (Pubitemid 351803953)
12. Ellem SJ, Wang H, Poutanen M, Risbridger GP,. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am J Pathol. 2009; 175: 1187-1199.
13. Ellem SJ, Risbridger GP,. Aromatase and regulating the estrogen:androgen ratio in the prostate gland. J Steroid Biochem Mol Biol. 2010; 118: 246-251.
14. Bonkhoff H, Berges R,. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol. 2009; 55: 533-542.
15. Carruba G,. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem. 2007; 102: 899-911. (Pubitemid 350036930)
16. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK,. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009; 73: 356-361.
17. Heracek J, Urban M, Sachova J, et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett. 2007; 28: 45-51. (Pubitemid 46291146)
18. Giton F, de la Taille A, Allory Y, et al. Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa). J Steroid Biochem Mol Biol. 2008; 109: 158-167.
19. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009; 27: 4300-4305.
20. Wright JL, Salinas CA, Lin DW, et al. Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4+3 and Gleason 3+4 tumors in a population based cohort. J Urol. 2009; 182: 2702-2707.
21. Green FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
22. Kuroiwa K, Shiraishi T, Ogawa O, et al. Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol. 2010; 183: 952-957.
23. National Committee for Clinical Laboratory Standards (NCCLS). How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory; Approved Guidelines (NCCLS Document C28-A). Villanova, PA: NCCLS; 1995.
24. Mazumdar M, Glassman JR,. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000; 19: 113-132. (Pubitemid 30051256)
25. Shariat SF, Walz J, Roehrborn CG, et al. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol. 2008; 26: 1526-1531.
26. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169: 1670-1675. (Pubitemid 36443468)
27. Pelzer AE, Colleselli D, Bektic J, et al. Clinical and pathological features of screen vs non-screen-detected prostate cancers: is there a difference? BJU Int. 2008; 102: 24-27. (Pubitemid 351799445)
28. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009; 55: 121-130.
29. Carruba G,. Estrogens and mechanisms of prostate cancer progression. Ann N Y Acad Sci. 2006; 1089: 201-217. (Pubitemid 47092082)
30. Fujimura T, Takahashi S, Urano T, et al. Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer. Cancer Sci. 2010; 101: 646-651.
31. Mak P, Leav I, Pursell B, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010; 17: 319-332.
32. Dondi D, Piccolella M, Biserni A, et al. Estrogen receptor beta and the progression of prostate cancer: role of 5alpha-androstane-3beta,17beta-diol. Endocr Relat Cancer. 2010; 17: 731-742.
33. Leung YK, Lam HM, Wu S, et al. Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer. 2010; 17: 675-689.
34. Sugiyama N, Barros RP, Warner M, Gustafsson JA,. ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab. 2010; 21: 545-552.
35. Dwyer MA, Joseph JD, Wade HE, et al. WNT11 expression is induced by estrogen-related receptor α- and β-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res. 2010; 70: 9298-9308.
36. Weihua Z, Makela S, Andersson LC, et al. A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A. 2001; 98: 6330-6335. (Pubitemid 32492315)
37. Horvath LG, Henshall SM, Lee CS, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001; 61: 5331-5335. (Pubitemid 32694904)
38. Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B,. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986; 76: 45-48. (Pubitemid 16156102)
39. Bosland MC,. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000; 27: 39-66.
40. Morgentaler A,. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2009; 181: 972-979.
41. Ide H, Yasuda M, Nishio K, et al. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels. Anticancer Res. 2008; 28: 2487-2492.
42. Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB,. Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging. BJU Int. 2010; 105: 824-829.
43. Fodstad P, Bjoro T, Torlakovic G, Fossa SD,. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol. 2002; 168: 1188-1192.
44. Lee SE, Chung JS, Han BK, et al. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer. Eur Urol. 2008; 54: 1324-1332.
45. Gallina A, Karakiewicz PI, Hutterer GC, et al. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer. 2007; 121: 791-795. (Pubitemid 47106208)
46. Banez LL, Sun L, Trock BJ, et al. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009; 182: 491-496.
47. Vermeulen A, Verdonck L, Kaufman JM,. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999; 84: 3666-3672. (Pubitemid 30645223)
48. Labrie F, Belanger A, Belanger P, et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. 2006; 99: 182-188. (Pubitemid 43766081)
49. Suzuki K, Nishiyama T, Hara N, Yamana K, Takahashi K, Labrie F,. Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis. 2007; 10: 301-306. (Pubitemid 47351410)